Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 411 across all filing types
Latest filing 2026-05-04 Declaration of Voting R…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Avril 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements
2026-05-04 French
bioMérieux – First-Quarter 2026 Business Review
Earnings Release Classification · 1% confidence The document is a press release titled “First-Quarter 2026 Business Review” with summary financial performance, organic sales trends, guidance revision, and key metrics for Q1 2026. It provides headline quarter results, product/regional breakdown tables, commentary by the CEO, and a link to an upcoming investor presentation. This matches the definition of an Earnings Release (ER) – the initial announcement of quarterly financial results with key highlights. It is not a full interim/quarterly report (IR) but a summary release of Q1 results. Therefore, filing code ER is appropriate. Q1 2026
2026-04-23 English
bioMérieux – Information financière du 1er trimestre 2026
Earnings Release Classification · 1% confidence The document is a press release presenting bioMérieux’s first-quarter 2026 financial results: it includes key highlights (organic revenue growth, major product performance), tables of revenue by application and region, management commentary, outlook revision, webcast invitation, and financial calendar. This is the initial announcement of quarterly results rather than a full interim report or an announcement pointing to a separate document. Therefore it is classified as an Earnings Release. Q1 2026
2026-04-23 French
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
Regulatory Filings Classification · 0% confidence The document is a corporate news release from bioMérieux announcing the publication of a multi‐country health economic analysis on rapid diagnostics in sepsis care. It is not an annual, interim, or earnings report; it does not describe board or capital changes, voting results, or legal proceedings; nor is it a detailed investor presentation or financial supplement. It primarily serves as a press release and does not neatly fit into any specific category. Therefore, it falls into the fallback category of a general regulatory announcement (RNS).
2026-04-20 English
Une étude médico-économique menée pour la première fois dans les pays du G7 démontre que le recours précoce à des tests de diagnostic rapides face au sepsis pourrait sauver des milliers de vies et gén
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing the publication of an external medico-economic analysis by the Office of Health Economics. It contains no financial results presentation (beyond a summary of the study’s economic impact), no regulatory form names, no earnings figures in a results-release style, and no changes to board, capital structure, dividends, or management. It is not itself an annual or interim report, nor an investor presentation of company strategy. Instead, it is a general announcement of a study’s availability. Since it does not fit any specific filing category, it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-20 French
bioMérieux lance sa solution de diagnostic moléculaire BIOFIRE® SPOTFIRE® pour l’industrie pharmaceutique afin de renforcer le dépistage rapide des mycoplasmes
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing the launch of a new diagnostic product (BIOFIRE SPOTFIRE) for the pharmaceutical industry. It does not contain financial results or regulatory filings such as an annual or interim report, earnings release, capital change, or board changes. Instead, it is a standard product announcement/press release with company background and contact information. No specific meeting materials, financial data, or regulatory process is described. Therefore, it falls into the fallback category for miscellaneous announcements: Regulatory Filings (RNS).
2026-04-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.